Article

Eye drop royalties benefit Schepens research

Woburn, MA-Advanced Vision Research Inc.'s royalty payments have made it the single largest private benefactor of The Schepens Eye Research Institute.

Woburn, MA-Advanced Vision Research Inc.'s royalty payments have made it the single largest private benefactor of The Schepens Eye Research Institute.

The company has paid more than $1.5 million to the institute as part of its agreement to license the patents developed there by Jeffrey P. Gilbard, MD.

Dr. Gilbard studied dry eye while at the institute from 1980 to 1995, and developed the TheraTears Brand Lubricant Eye Drops as a result of an 18-year research project funded by the National Institutes of Health. He went on to found Advanced Vision Research, and serves as its chief executive officer and chief scientific officer.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.